CreativeOne Wealth LLC Invests $211,000 in AstraZeneca PLC (NASDAQ:AZN)

CreativeOne Wealth LLC purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,712 shares of the company’s stock, valued at approximately $211,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Martin Investment Management LLC lifted its holdings in shares of AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC lifted its holdings in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning lifted its holdings in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after purchasing an additional 16,692 shares in the last quarter. Northcape Wealth Management LLC purchased a new stake in shares of AstraZeneca in the second quarter valued at about $269,000. Finally, Optas LLC lifted its holdings in shares of AstraZeneca by 173.5% in the third quarter. Optas LLC now owns 15,570 shares of the company’s stock valued at $1,213,000 after purchasing an additional 9,877 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $68.05 on Wednesday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a 50 day moving average price of $71.89 and a 200 day moving average price of $77.31. The firm has a market capitalization of $211.00 billion, a price-to-earnings ratio of 32.56, a price-to-earnings-growth ratio of 1.23 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the business posted $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. Sell-side analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.